Treatment with mesalamine significantly reduced SPHK and S1P levels by 34.04% (F = 582.9, p = 0.0004) and 22.64% (F = 1755, p = 0.003), respectively, relative to the colitis group. This evidence concerns the gene SPHK1 and colitis.